VitriVax Receives Grant From the Coalition for Epidemic Preparedness Innovations (CEPI) to Leverage ALTA® Technology for Single-Dose Rabies Vaccine
VitriVax, Inc., a formulation technology company, announced a new grant of up to $5M from the Coalition for Epidemic Preparedness Innovations (CEPI). The grant will enable VitriVax to develop the Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology further using Rabies as a vaccine target. ALTA® could replace multi-dose vaccines for protection against infectious diseases with a single-administration alternative. The company’s innovative approach in the pharma industry, known as ‘atomic layering deposition’, is used to control the release of the vaccine in the body over time.
VitriVax Awarded $3.6M Grant for Polio Vaccine Development
VitriVax, Inc., a vaccine formulation technology company, announced today a two-year $3.6 million grant from the Bill & Melinda Gates Foundation. This is the second grant awarded to VitriVax by the Gates Foundation and will fund development of a polio vaccine formulation for possible inclusion in combination pediatric vaccines.
VitriVax Receives $5M Grant for Vaccine Development
VitriVax, Inc., a formulation technology company, announced today a $5M two-year grant from the Bill & Melinda Gates Foundation.
VitriVax Awarded $29M DoD Contract to Fund Vaccine Research
VitriVax Inc., a formulation technology company, has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense.
